More than 4 million people in the U.S. have glaucoma, a group of eye diseases that can damage the optic nerve and lead to ...

Eye diseases like glaucoma, cataracts, and conjunctivitis are some of the more common types. Find eye disease awareness and ...

More than 4 million people in the U.S. have glaucoma, a group of eye diseases that can damage the optic nerve and lead to ...

Glaucoma encompasses a heterogeneous group of eye diseases associated with progressive loss of optic nerve fibers, with ...

Health care and tech innovation go hand in hand. From delivering steady streams of medication to speeding up treatment of ...

HOUSTON, TX / ACCESSWIRE / November 20, 2024 / Mann Eye Institute, a pioneer in innovative eye care since the 1970s, ...

Glaucoma risk can be managed more effectively with the ability to use polygenic risk scores to identify individuals who can ...

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...

Researchers at the University of Cambridge have found that a medication typically used to treat glaucoma might offer a new weapon in the fight against neurodegenerative ... and progressive ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

SpyGlass prepares for End of Phase II meeting with the FDA to advance its Drug Delivery Platform into Phase III pivotal studies; Innovative platform has the potential to enable al ...

Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal ...